Literature DB >> 22466343

Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer.

Jena D French1, Gregory R Kotnis, Sherif Said, Christopher D Raeburn, Robert C McIntyre, Joshua P Klopper, Bryan R Haugen.   

Abstract

CONTEXT: Recurrent metastatic lymph node (LN) disease is common in patients with papillary thyroid cancer (PTC). Novel prognostic markers may be helpful in guiding a therapeutic approach. Our previous studies revealed that immune suppression is evident in PTC and associated with more severe disease.
OBJECTIVE: To characterize the immune response to metastatic PTC, we assessed CD4(+) T cell polarization in LN. In addition, we investigated the role of programmed death-1 (PD-1) and T cell exhaustion.
DESIGN: Uninvolved (UILN) and tumor-involved lymph nodes (TILN) were sampled ex vivo by fine-needle biopsy. T cell subsets were identified by flow cytometry. In parallel, archived TILN specimens were characterized by immunofluorescence.
SETTING: The study was conducted at the University of Colorado Hospital. PATIENTS: Data were collected on 94 LN from 19 patients with PTC undergoing neck dissection. MAIN OUTCOME: T cell subset frequencies were compared in UILN and TILN and assessed for correlation with recurrent disease and extranodal invasion.
RESULTS: Regulatory CD4(+) T cells (Treg) were enriched in TILN compared with UILN and further elevated in TILN from patients with recurrent disease. PD-1(+) T cells were present at high frequency in TILN and markedly enriched in TILN that showed evidence of extranodal invasion. In TILN, Treg frequency correlated with PD-1(+) T cell frequencies. Although PD-1(+) T cells produced interferon-γ, they failed to fully down-regulate CD27 and were not actively proliferating.
CONCLUSIONS: Increased Treg and PD-1(+) T cell frequencies in LN may be indicative of aggressive recurrent PTC. Future prospective studies are necessary to determine the prognostic and therapeutic value of these findings in PTC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22466343      PMCID: PMC3387418          DOI: 10.1210/jc.2011-3428

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  Transient gain of effector function by CD8+ T cells undergoing peripheral tolerance to high-dose self-antigen.

Authors:  Xiaopei Huang; Yiping Yang
Journal:  Eur J Immunol       Date:  2004-05       Impact factor: 5.532

2.  Interleukin-17 promotes angiogenesis and tumor growth.

Authors:  Muneo Numasaki; Jun-ichi Fukushi; Mayumi Ono; Satwant K Narula; Paul J Zavodny; Toshio Kudo; Paul D Robbins; Hideaki Tahara; Michael T Lotze
Journal:  Blood       Date:  2002-10-31       Impact factor: 22.113

3.  Activation-induced expression of human programmed death-1 gene in T-lymphocytes.

Authors:  R Vibhakar; G Juan; F Traganos; Z Darzynkiewicz; L R Finger
Journal:  Exp Cell Res       Date:  1997-04-10       Impact factor: 3.905

4.  Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection.

Authors:  David G Brooks; Luc Teyton; Michael B A Oldstone; Dorian B McGavern
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Antigen-independent memory CD8 T cells do not develop during chronic viral infection.

Authors:  E John Wherry; Daniel L Barber; Susan M Kaech; Joseph N Blattman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

6.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

7.  Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.

Authors:  E John Wherry; Joseph N Blattman; Kaja Murali-Krishna; Robbert van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors.

Authors:  A S Dighe; E Richards; L J Old; R D Schreiber
Journal:  Immunity       Date:  1994-09       Impact factor: 31.745

9.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

10.  Variations in lymphokine generation by individual lymph nodes draining human malignant tumors.

Authors:  D R Wen; D S Hoon; C Chang; A J Cochran
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more
  50 in total

1.  Immune Escape Mechanism is Impaired in the Microenvironment of Thyroid Lymph Node Metastasis.

Authors:  Lucas Leite Cunha; Suely Nonogaki; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Endocr Pathol       Date:  2017-12       Impact factor: 3.943

2.  Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway.

Authors:  C Visciano; F Liotti; N Prevete; G Cali'; R Franco; F Collina; A de Paulis; G Marone; M Santoro; R M Melillo
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

3.  Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.

Authors:  Arutselvan Natarajan; Aaron T Mayer; Robert E Reeves; Claude M Nagamine; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

Review 4.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

5.  Positive effect of RORγt on the prognosis of thyroid papillary carcinoma patients combined with Hashimoto's thyroiditis.

Authors:  Rong Zeng; Yi Lyu; Guoqiao Zhang; Tao Shou; Kai Wang; Heng Niu; Xinmin Yan
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

Review 6.  Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.

Authors:  Heewa Shakib; Sadegh Rajabi; Mohammad Hossien Dehghan; Farideh Jalali Mashayekhi; Nahid Safari-Alighiarloo; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-08-04       Impact factor: 3.633

Review 7.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

8.  Association of PDCD1 gene markers with susceptibility to thyroid cancer.

Authors:  M R Haghshenas; M H Dabbaghmanesh; A Miri; A Ghaderi; N Erfani
Journal:  J Endocrinol Invest       Date:  2016-12-09       Impact factor: 4.256

9.  PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Authors:  Matthew W Rosenbaum; Benjamin J Gigliotti; Sara I Pai; Sareh Parangi; Heather Wachtel; Mari Mino-Kenudson; Viswanath Gunda; William C Faquin
Journal:  Endocr Pathol       Date:  2018-03       Impact factor: 3.943

10.  The distribution of cutaneous metastases correlates with local immunologic milieu.

Authors:  Joshua M Schulman; Mariela L Pauli; Isaac M Neuhaus; Roberto Sanchez Rodriguez; Keyon Taravati; Uk Sok Shin; Timothy H McCalmont; Michael D Rosenblum
Journal:  J Am Acad Dermatol       Date:  2016-01-09       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.